(CLBT) Cellebrite DI - Ratings and Ratios
Exchange: NASDAQ • Country: Israel • Currency: USD • Type: Common Stock • ISIN: IL0011794802
CLBT: Software, Solutions, Tools, Services, Forensics, Management
Cellebrite DI Ltd. (NASDAQ:CLBT) is a global leader in digital intelligence solutions, operating across Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The companys DI suite of solutions is designed to support legally sanctioned investigations by enabling the collection, review, analysis, and management of digital data across the entire investigative lifecycle. This is critical in cases such as child exploitation, homicide, anti-terrorism, border control, sexual crimes, human trafficking, corporate security, cryptocurrency investigations, and intellectual property theft.
The companys flagship product, Inseyets, is a digital forensics software that excels at collecting and reviewing digital evidence from a wide range of digital sources. It also offers advanced capabilities such as data extraction, decoding, workflows, and automation, which are essential for modern investigative workflows. Beyond Inseyets, Cellebrite offers Cellebrite Pathfinder, a tool that significantly reduces manual review time by automating data analysis and visualization. This is a game-changer for overburdened investigative teams. Additionally, the company provides Smart Search, an open-source intelligence tool that automates the collection and review of publicly available online data, and Guardian, a comprehensive case and evidence management solution.
For enterprises and service providers, Cellebrite offers a suite of digital forensic software solutions, including Inseyets for Enterprise, Endpoint Inspector, and Mobile Now. These tools are designed to meet the specific needs of organizations dealing with internal investigations, cybersecurity threats, and data protection. The company also provides professional services such as training and certification programs, ensuring that users can maximize the effectiveness of its solutions. Cellebrite primarily serves federal, state, and local agencies, positioning itself as a trusted partner for law enforcement and investigative bodies worldwide.
Headquartered in Petah Tikva, Israel, Cellebrite has established itself as a leader in the digital forensics and intelligence space. With a market capitalization of $4.4 billion, the company trades on the NASDAQ under the ticker symbol CLBT. Its forward P/E ratio of 37.17 and P/S ratio of 11.43 reflect its growth trajectory and the markets confidence in its ability to scale. Cellebrites focus on innovation, coupled with its SaaS-based model, positions it well to capitalize on the growing demand for digital intelligence solutions in both the public and private sectors.
Additional Sources for CLBT Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CLBT Stock Overview
Market Cap in USD | 4,495m |
Sector | Technology |
Industry | Software - Infrastructure |
GiC Sub-Industry | Application Software |
IPO / Inception | 2021-08-31 |
CLBT Stock Ratings
Growth Rating | 52.1 |
Fundamental | 59.4 |
Dividend Rating | 0.0 |
Rel. Strength | 80.4 |
Analysts | 4.75/5 |
Fair Price Momentum | 18.20 USD |
Fair Price DCF | 9.94 USD |
CLBT Dividends
No Dividends PaidCLBT Growth Ratios
Growth Correlation 3m | -66.6% |
Growth Correlation 12m | 87.8% |
Growth Correlation 5y | 36.8% |
CAGR 5y | 16.26% |
CAGR/Max DD 5y | 0.24 |
Sharpe Ratio 12m | 0.87 |
Alpha | 71.12 |
Beta | 1.525 |
Volatility | 55.00% |
Current Volume | 991.2k |
Average Volume 20d | 1208.6k |
As of April 11, 2025, the stock is trading at USD 18.82 with a total of 991,198 shares traded.
Over the past week, the price has changed by +0.27%, over one month by +12.16%, over three months by -12.75% and over the past year by +72.50%.
Partly, yes. Based on ValueRay Fundamental Analyses, Cellebrite DI (NASDAQ:CLBT) is currently (April 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 59.36 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CLBT as of April 2025 is 18.20. This means that CLBT is currently overvalued and has a potential downside of -3.29%.
Cellebrite DI has received a consensus analysts rating of 4.75. Therefor, it is recommend to buy CLBT.
- Strong Buy: 6
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, CLBT Cellebrite DI will be worth about 20.6 in April 2026. The stock is currently trading at 18.82. This means that the stock has a potential upside of +9.62%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 28 | 48.8% |
Analysts Target Price | 23.3 | 23.8% |
ValueRay Target Price | 20.6 | 9.6% |